Neuroptix Corporation


Senior Management Team

Susanne Wilke, Ph.D., MBA

Appointed CEO of Cognoptix in January 2019, Dr. Wilke is an experienced executive with over 30 years of experience in drug development and Venture Capital Financing in senior positions in Pharma, Biotech, Venture Capital and Healthcare Consulting. She has extensive pharmaceutical research and drug development, operating, investing, financing and commercial experience. Prior to joining Cognoptix, Dr. Wilke served as the CEO and a Director of Neurotrope Biosciences (NTRP), a NASDAQ - listed clinical-stage biotech company which focuses on an innovative new mechanism of action for neurodegenerative diseases, including Alzheimer's Disease. While the CEO of Neurotrope, Dr. Wilke instituted a transformative strategy and business plan that encompassed financial, clinical, operational and commercial changes. She restructured Neurotrope, raised $26m of equity, in-licensed from Stanford University the critically important synthetic route for its lead, Bryostatin, up-listed Neurotrope to NASDAQ, built out the scientific advisory board and advanced the company clinically. Prior still, Dr. Wilke was founder and Managing Partner of CrossBridge International, an internationally active healthcare Advisory Firm focused on Healthcare Strategy and Capital Formation.  Prior to that, Dr. Wilke was a Worldwide Director of Commercial Assessment and In-licensing for Forest Labs, a specialty pharmaceutical company based in New York. At Forest Labs, Dr. Wilke led cross-functional due diligence teams across a wide variety of indications, including, CNS, oncology cardiovascular and orphan diseases.  While at Forest Labs, Dr. Wilke worked extensively on reimbursement strategies.  Early in her career, Dr. Wilke was a team leader at Roche Pharma in Metabolic Disease. She also served as team leader for the planning and set-up of Amgen's research efforts in Cambridge, MA and was program manager for its Gene Therapy efforts.  Dr. Wilke  spent over five years in Venture Capital with SV Life Sciences in Boston and NGN Capital in New York, where she was involved in several winning investments like Rinat, GlycoFi and Sightline.

Dr. Wilke holds an MBA in general management and finance from the Tuck School of Business at Dartmouth, a dual degree chemistry and biochemistry with focus on drug development from University of Illinois, and a BS from Loyola University.  Dr. Wilke also served as a prestigious Kauffman Fellow.

Tom Trometer, Chief Financial Officer

With over 25 years of experience, and with a strong track record in CFO leadership positions, Tom is responsible for the financial management of Neuroptix’s operations. In this role he provides oversight for the financial management of the business, directs the corporate treasury function, establishes the protocols and standards for internal reporting, including Human Resources, and assists in building the business model and plan, shareholder communication, and risk management for the company. Prior to forming his own practice, he was VP Finance and CFO of CableSoft, and was instrumental in raising capital and selling the company to Motorola.  Before CableSoft, Tom was VP of Finance and Treasurer of Opta Food Ingredients, a public company, and was instrumental in raising over $40M in equity funds. He was also a manager in the Middle Market and Growing Companies Division of Price Waterhouse Coopers.  Tom is a CPA with a BS in accounting from Canisius College in Buffalo, NY.

Joyce E. Myers, MD, Vice President, Clinical Development

Dr. Myers is board certified in Diagnostic Radiology and Psychiatry with 30 years of both clinical and research experience in academics and industry, primarily in psychiatry and neuropharmacology.  She received her BA and MD at Temple University.  She completed residency training in diagnostic radiology and psychiatry. While at the Western Psychiatric Institute and Clinic she completed a residency and fellowship in Mood Disorders and Neuropharmacology before joining the faculty.  She has held numerous positions both in clinical practice and the pharmaceutical industry.  While at Boehringer Ingelheim she was involved in the development of Talsaclidine for the treatment of Alzheimer's disease. She was also responsible for the regulatory  approval of Micardis  for use in the management of hypertension.  As Director for CNS Medial Affairs at Janssen Pharmaceutica she worked on the clinical development of Risperdal and Topamax in the treatment of mood disorders.

Dennis Nilan, Director Project Management

With over 25 years of experience in the medical device industry, Dennis has broad experience in research and development, clinical trials management, operations, and regulatory affairs.  He oversees all project management, drug development and manufacturing, device development and manufacturing, regulatory and quality functions. Prior to joining Cognoptix, Dennis held various positions at the medical device startup companies of Optos and Summit Technology.  He has a strong background in medical laser eye care both nationally and globally.